The attributable fraction of respiratory syncytial virus among patients of different age with influenza-like illness and severe acute respiratory illness in a high HIV prevalence setting, South Africa, 2012-2016

Competing Interest Statement

Prof Cheryl Cohen and Anne von Gottberg has received institutional funding support from US CDC related to the current work and also received funding from Bill and Melinda Gates Foundation (BMGF), PATH, Sanofi, Wellcome Trust and South African MRC outside of the submitted work. Dr Moyes received institutional funding from Sanofi and PATH for work outside of this current work. Dr Dawood reports personal fees from Sanofi-South Africa. In addition, she reports workshop attendance sponsorship from Biomieruex-South Africa.

Funding Statement

The data collection for this manuscript was funded through a grant to the NICD from the Centers for Disease Control (CDC), Atlanta Georgia. Collaborative Research on Influenza, Coronavirus Diseases 2019 (COVID-19), and Other Respiratory Pathogens in South Africa (Cooperative Agreement Number: 1U01IP001160)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approval for the hospital-based surveillance was obtained from the University of the Witwatersrand Human Research Ethics Committee (HREC) for the Klerksdorp site and form the University of KwaZulu-Natal Human Biomedical Research Ethics Committee (BREC) for the Pietermaritzburg site; protocol numbers M081042 and BF157/08, respectively. The ILI and control enrolment protocol was approved by HREC and BREC (protocol numbers M120133 and BF080/12, respectively). This surveillance was deemed non-research by the US Centers for Disease Control and Prevention (non-research determination number: 2012-6197).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes